November 5, 2014 | The Israeli pharmaceutical company Teva and Active Biotech will expand the Laquinimod clinical development program into Phase II trials. The trials will evaluate the ability of the Laquinimod drug to treat primary progressive multiple sclerosis (PPMS) as well as Huntington’s disease. This would be the first treatment for both PPMS and Huntington’s disease beyond symptom management. The study, called ARPEGGIO, will evaluate the efficacy, safety and tolerability of the Laquinimod drug in patients with PPMS, and the LEGATO-HD trial will test the efficacy and safety of the drug use on individuals with Huntington’s disease. Teva Pharmaceutical Industries was founded in 1901 by Eli Hurvitz.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments